DOCSLIB.ORG

The Anti-Tubercular Activity of Simvastatin Is Mediated by Cholesterol-Dependent Regulation Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Anti-Tubercular Activity of Simvastatin Is Mediated by Cholesterol-Dependent Regulation Of bioRxiv preprint doi: https://doi.org/10.1101/2020.03.04.977579; this version posted March 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The anti-tubercular activity of simvastatin is mediated by cholesterol-dependent regulation of 2 autophagy via the AMPK-mTORC1-TFEB axis. 3 4 Natalie Bruiners1, Noton K. Dutta2, Valentina Guerrini1, Hugh Salamon3, Ken D. Yamaguchi3, Petros C. 5 Karakousis2, 4, Maria L. Gennaro1,* 6 7 1Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New 8 Jersey, NJ. 9 2Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of 10 Medicine, Baltimore, MD. 11 3Knowledge Synthesis Inc., Berkeley, CA. 12 4Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 13 14 Running title: Simvastatin induces autophagy through the AMPK-mTORC1-TFEB axis 15 16 Keywords. Mycobacterium tuberculosis, simvastatin, cholesterol, autophagy, macrophages, mTOR, TFEB 17 18 *Corresponding author: 19 Public Health Research Institute 20 New Jersey Medical School 21 Rutgers University 22 225 Warren Street, Newark, NJ 07103. 23 Tel: 973-854-3210; Fax: 973-854-310; e-mail address: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.03.04.977579; this version posted March 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 24 ABSTRACT 25 Statins, which inhibit both cholesterol biosynthesis and protein prenylation branches of the mevalonate 26 pathway, increase anti-tubercular antibiotic efficacy in animal models. We investigated the mechanism of 27 anti-tubercular action of simvastatin in Mycobacterium tuberculosis-infected human monocytic cells. We 28 found that the anti-tubercular activity of statins was phenocopied by cholesterol-branch but not prenylation- 29 branch inhibitors. Moreover, statin treatment blocked activation of mechanistic target of rapamycin 30 complex 1 (mTORC1), activated AMP-activated protein kinase (AMPK) through increased intracellular 31 AMP:ATP ratios, and favored nuclear translocation of transcription factor EB (TFEB). These mechanisms 32 all induce autophagy, which is anti-mycobacterial. The biological effects of simvastatin on the AMPK- 33 mTORC1-TFEB-autophagy axis were reversed by adding exogenous cholesterol to the cells. Overall, our 34 data demonstrate that the anti-tubercular activity of simvastatin requires inhibiting cholesterol biosynthesis, 35 reveal novel links between cholesterol homeostasis, AMPK-mTORC1-TFEB axis, and intracellular 36 infection control, and uncover new anti-tubercular therapy targets. 2 bioRxiv preprint doi: https://doi.org/10.1101/2020.03.04.977579; this version posted March 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 37 1. INTRODUCTION 38 As our knowledge of host-pathogen interactions grows for many infectious agents, pharmacologically 39 manipulating the host response has emerged as a key approach to control or treat disease-causing infections. 40 This approach may be best suited for infections caused by intracellular pathogens, given the intimate 41 relationship between these pathogens and their host cells. For example, Mycobacterium tuberculosis, the 42 intracellular pathogen causing tuberculosis, can subvert and disable the antimicrobial mechanisms of the 43 host macrophage while adapting to the environmental conditions created by these mechanisms (1, 2). The 44 treatment of active tuberculosis, which typically presents with lung tissue damage, is prolonged and requires 45 multiple drugs, presumably due to the presence of phenotypically diverse M. tuberculosis subpopulations 46 that exhibit antibiotic tolerance and poor penetration of antibiotics into infected tissues (3-5). The prolonged 47 duration of anti-tubercular antibiotic therapy (a minimum of six months for drug-susceptible, 48 uncomplicated tuberculosis) poses logistical difficulties for treatment providers and leads to poor patient 49 compliance, particularly in low-resource regions (6). A dramatic consequence of these challenges is the 50 development of antibiotic resistance, which requires treatments that are even more prolonged, less effective, 51 more expensive, and more toxic (7). 52 53 One strategy that can address the above challenges is utilizing adjunctive chemotherapies that modify host 54 responses to infection to reduce inflammation and tissue damage and/or to promote infection clearance (8). 55 These host-directed therapies may shorten treatment duration, combat antibiotic-resistant disease by 56 helping reduce its incidence, and improve treatment success, since it is unlikely that cross-resistance 57 develops between antibiotics and host-directed therapeutics. The renewed attention to host-directed 58 therapeutics warrants elucidating their mechanism of action in the context of the target infectious disease. 59 Among the current drugs under evaluation as host-directed therapeutics against tuberculosis are statins (9- 60 13). These drugs, which are prescribed worldwide as cholesterol-lowering agents, act by competitively 61 inhibiting 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme of the 3 bioRxiv preprint doi: https://doi.org/10.1101/2020.03.04.977579; this version posted March 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 62 mevalonate pathway (14). This pathway regulates biosynthesis of cholesterol and isoprenoids, such as 63 farnesyl pyrophosphate and geranylgeranyl pyrophosphate. The latter molecules are needed for protein 64 prenylation, a process that activates and targets to membranes several protein classes that regulate cell 65 growth, differentiation, and cell function (15). Consequently, statins not only possess cholesterol-lowering 66 activity, but also exhibit pleotropic effects, such as tissue remodeling, inhibition of vascular inflammation, 67 cytokine production, and immunomodulation (16, 17). 68 69 Due to their pleotropic effects, statins are currently under investigation in many pathological contexts. For 70 example, their use has been explored against multisystem microbial infections, such as sepsis and 71 pneumonia, and in non-infectious pathologies, such as autoimmune and inflammatory diseases (18-20). In 72 regard to tuberculosis, statins exhibit anti-tubercular activity in murine and human macrophages infected 73 ex vivo (9, 12, 13), display immunomodulatory effects in ex vivo infected human peripheral blood cells 74 (13), and shorten the duration of antibiotic treatment in M. tuberculosis-infected mice (10, 11). Previous 75 work (9) found a reduction in M. tuberculosis burden in murine macrophages by high doses of statins that 76 inhibited both the cholesterol- and isoprenoid-forming branches of the mevalonate pathway. These effects 77 were ascribed to the induction of autophagy, which controls M. tuberculosis infection (21-23), through the 78 inhibition of geranylgeranyl biosynthesis, as observed in coronary arterial myocytes and certain cancer cell 79 lines (24, 25). The molecular mechanisms underlying these results and the significance of effects induced 80 by statin doses that far exceed therapeutic dosing remained unexplained. By utilizing simvastatin to treat 81 M. tuberculosis-infected human monocytic cells, we now show that the anti-tubercular activity of statins 82 results from their cholesterol-lowering effects and the consequent regulation of the nutrient- and energy- 83 sensing pathways regulated by the AMP-activated protein kinase (AMPK), the mechanistic target of 84 rapamycin complex 1 (mTORC1), and the transcription factor EB (the AMPK-mTORC1-TFEB axis), in 85 ways that promote autophagy and control of infection with intracellular pathogens. 86 87 4 bioRxiv preprint doi: https://doi.org/10.1101/2020.03.04.977579; this version posted March 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 88 2. RESULTS 89 2.1. Simvastatin limits M. tuberculosis infection by inhibiting de novo synthesis of cholesterol 90 The mevalonate pathway, which is the mechanistic target of statins, is multi-branched (Fig. 1A). Identifying 91 the pathway branch(es) associated with the observed anti-tubercular activity of these compounds is the first 92 step toward elucidating the underlying mechanism of action. Treatment of M. tuberculosis-infected THP1 93 cells (a human monocytic cell line) with simvastatin, demonstrated that this drug decreased M. tuberculosis 94 intracellular burden (Fig. 1 B), consistent with previous reports (11, 12). The anti-mycobacterial effect of 95 simvastatin varied with the dose, with concentrations of 50-100 nM being the most effective (Fig. 1B). 96 Additional experiments determined that these anti-mycobacterial doses were non-toxic for THP1 cells 97 (supplementary Fig. 1A) and that simvastatin had no direct antimicrobial activity against M. tuberculosis 98 in axenic cultures (supplementary Fig. 1B). We next tested the effect on intracellular M. tuberculosis burden 99 of inhibitors
Load more

Recommended publications
  • Bacille Calmette–Guérin Vaccination: the Current Situation in Europe
    EDITORIAL BCG VACCINATION POLICY IN EUROPE | Bacille Calmette–Gue´rin vaccination: the current situation in Europe Masoud Dara1,5, Colleen D. Acosta1,5, Valiantsin Rusovich2, Jean Pierre Zellweger3, Rosella Centis4 and Giovanni Battista Migliori4 on behalf of the WHO EURO Childhood Task Force members6 Affiliations: 1World Health Organization Regional Office for Europe, Copenhagen, Denmark. 2World Health Organization Country Office, Minsk, Belarus. 3Swiss Lung Association, Vaud section (LPVD), Lausanne, Switzerland. 4World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy. 5These authors contributed equally. 6For a list of the WHO EURO Childhood Task Force members and their affiliations, please see the acknowledgements section. Correspondence: G.B. Migliori, World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Via Roncaccio 16, 21049, Tradate, Italy. E-mail: [email protected] @ERSpublications A WHO EURO Task Force provides the latest evidence and a coherent policy to use BCG vaccination in Europe http://ow.ly/pusIU Tuberculosis is a major public health priority. This is not only because of its daunting morbidity and mortality rates, both globally and in Europe (summarised in figs 1 and 2)[1, 3–5], but also because of the natural history of the disease. Active (contagious) tuberculosis disease occurs after a period of latency (or subclinical infection), and different risk factors [6–13], in combination with latent infection, introduce challenges to prevention, diagnosis and treatment of the disease. Vaccination against tuberculosis, if effective, would be therefore critical to control and elimination strategies [14–16].
    [Show full text]
  • Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis ISBN 978 92 4 154880 9
    Companion handbookCompanion tofor the the WHO programmatic guidelines management of drug-resistant tuberculosis Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis ISBN 978 92 4 154880 9 Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis This book is a companion handbook to existing WHO policy guidance on the management of multidrug-resistant tuberculosis, including the WHO guidelines for the programmatic management of drug-resistant tuberculosis, WHO interim policy guidance on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis, and the WHO interim policy guidance on the use of delamanid in the treatment of multidrug-resistant tuberculosis which were developed in compliance with the process for evidence gathering, assessment and formulation of recommendations, as outlined in the WHO Handbook for Guideline Development (version March 2010; available at http://apps.who.int/iris/ bitstream/10665/75146/1/9789241548441_eng.pdf ). WHO Library Cataloguing-in-Publication Data Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. 1.Antitubercular agents – administration and dosage. 2.Tuberculosis, Multidrug-Resistant – drug therapy. 3.Treatment outcome. 4.Guideline. I.World Health Organization. ISBN 978 92 4 154880 9 (NLM classification: WF 360) © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.
    [Show full text]
  • Structural, Biochemical, and Cell Biological Characterization of Rab7 Mutants That Cause Peripheral Neuropathy
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations Spring 2010 Structural, Biochemical, and Cell Biological Characterization of Rab7 Mutants That Cause Peripheral Neuropathy Brett A. McCray University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Molecular and Cellular Neuroscience Commons Recommended Citation McCray, Brett A., "Structural, Biochemical, and Cell Biological Characterization of Rab7 Mutants That Cause Peripheral Neuropathy" (2010). Publicly Accessible Penn Dissertations. 145. https://repository.upenn.edu/edissertations/145 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/145 For more information, please contact [email protected]. Structural, Biochemical, and Cell Biological Characterization of Rab7 Mutants That Cause Peripheral Neuropathy Abstract Coordinated trafficking of intracellular vesicles is of critical importance for the maintenance of cellular health and homeostasis. Members of the Rab GTPase family serve as master regulators of vesicular trafficking, maturation, and fusion by reversibly associating with distinct target membranes and recruiting specific effector proteins. Rabs act as molecular switches by cycling between an active, GTP-bound form and an inactive, GDP-bound form. The activity cycle is coupled to GTP hydrolysis and is tightly controlled by regulatory proteins such as guanine nucleotide exchange factors and GTPase activating proteins. Rab7 specifically regulates the trafficking and maturation of vesicle populations that are involved in protein degradation including late endosomes, lysosomes, and autophagic vacuoles. Missense mutations of Rab7 cause a dominantly-inherited axonal degeneration known as Charcot-Marie-Tooth type 2B (CMT2B) through an unknown mechanism. Patients with CMT2B present with length-dependent degeneration of peripheral sensory and motor neurons that leads to weakness and profound sensory loss.
    [Show full text]
  • Management of Patients with Multidrug-Resistant Tuberculosis
    INT J TUBERC LUNG DIS 23(6):645–662 STATE OF THE ART Q 2019 The Union http://dx.doi.org/10.5588/ijtld.18.0622 STATE OF THE ART SERIES MDR-TB Series editors: C Horsburgh, Christoph Lange and Carole Mitnick NUMBER 4 IN THE SERIES Management of patients with multidrug-resistant tuberculosis C. Lange, R. E. Aarnoutse, J. W. C. Alffenaar, G. Bothamley, F. Brinkmann, J. Costa, D. Chesov, R. van Crevel, M. Dedicoat, J. Dominguez, R. Duarte, H. P. Grobbel, G. Gunther,¨ L. Guglielmetti, J. Heyckendorf, A. W. Kay, O. Kirakosyan, O. Kirk, R. A. Koczulla, G. G. Kudriashov, L. Kuksa, F. van Leth, C. Magis-Escurra, A. M. Mandalakas, B. Molina-Moya, C. A. Peloquin, M. Reimann, R. Rumetshofer, H. S. Schaaf, T. Schon, ¨ S. Tiberi, J. Valda, P. K. Yablonskii, K. Dheda Please see Supplementary Data for details of all author affiliations. SUMMARY The emergence of multidrug-resistant tuberculosis availability of novel drugs such as bedaquiline allow us to (MDR-TB; defined as resistance to at least rifampicin design potent and well-tolerated personalised MDR-TB and isoniazid) represents a growing threat to public treatment regimens based solely on oral drugs. In this health and economic growth. Never before in the history article, we present management guidance to optimise the of mankind have more patients been affected by MDR- diagnosis, algorithm-based treatment, drug dosing and TB than is the case today. The World Health Organiza- therapeutic drug monitoring, and the management of tion reports that MDR-TB outcomes are poor despite adverse events and comorbidities, associated with MDR- staggeringly high management costs.
    [Show full text]
  • Evans Sagwa Aukje K
    Optimizing the Safety of Multidrug-resistant Tuberculosis Therapy in Namibia Evans L. Sagwa Sagwa, EL Optimizing the Safety of Multidrug-resistant Tuberculosis Therapy in Namibia Thesis Utrecht University -with ref.- with summary in Dutch Copyright © 2017 EL Sagwa. All rights reserved. The research presented in this PhD thesis was conducted under the umbrella of the Utrecht World Health Organization (WHO) Collaborating Centre for Pharmaceutical Policy and Regulation, which is based at the Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht Uni- versity, The Netherlands. The Collaborating Centre aims to develop new methods for independent pharmaceutical policy research, evidence-based policy analysis and conceptual innovation in the area of policy making and evaluation in general. ISBN: 978-94-92683-40-3 Layout and printed by: Optima Grafische Communicatie, Rotterdam, the Netherlands Optimizing the Safety of Multidrug-resistant Tuberculosis Therapy in Namibia Verbeteren van de veiligheid van de behandeling van multiresistente tuberculose in Namibië (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op donderdag 24 augustus 2017 des middags te 12.45 uur door Evans Luvaha Sagwa geboren op 17 november 1972 te Kakamega, Kenia Promotor: Prof.dr. H.G.M. Leufkens Copromotor: Dr. A.K. Mantel-Teeuwisse A Quote by Donna Flagg: When the Cure Is Worse Than the Disease “Not only are the folks popping these pills not happy, but they now suffer from new problems that are caused by the drugs themselves”.
    [Show full text]
  • A Rab Escort Protein Regulates the MAPK Pathway That
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.02.130690; this version posted June 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Genome-Wide Screen for MAPK Regulatory Proteins Jamalzadeh and Cullen 1 A Rab Escort Protein Regulates the MAPK Pathway That 2 Controls Filamentous Growth in Yeast 3 4 Sheida Jamalzadeh 1 and Paul J. Cullen 2 † 5 1. Department of Chemical and Biological Engineering, University at Buffalo, State University 6 of New York, Buffalo New York 7 2. Department of Biological Sciences, University at Buffalo, State University of New York, 8 Buffalo New York 9 10 † Corresponding author: Paul J. Cullen 11 Address: Department of Biological Sciences 12 532 Cooke Hall 13 State University of New York at Buffalo 14 Buffalo, NY 14260-1300 15 Phone: (716)-645-4923 16 FAX: (716)-645-2975 17 E-mail: [email protected] 18 19 20 Keywords: Rab Escort Protein, MAP kinase, Cdc42, Protein Trafficking, Cell Polarity, 21 Genomics 22 23 Running title: Genome-Wide Screen for MAPK Regulatory Proteins 24 25 The authors have no competing interests in the study. 26 27 SJ designed and performed experiments, analyzed the data, and wrote the paper. PJC designed 28 experiments and wrote the paper. 29 30 The manuscript contains 32 pages, 6 Figures, 2 Tables, 3 Supplemental Tables, and 2 31 Supplemental Figures 32 33 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.02.130690; this version posted June 2, 2020.
    [Show full text]
  • Horizon Scanning Status Report, Volume 2
    PCORI Health Care Horizon Scanning System Volume 2, Issue 3 Horizon Scanning Status Report September 2020 Prepared for: Patient-Centered Outcomes Research Institute 1828 L St., NW, Suite 900 Washington, DC 20036 Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12 Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 Investigators: Randy Hulshizer, MA, MS Damian Carlson, MS Christian Cuevas, PhD Andrea Druga, PA-C Marcus Lynch, PhD, MBA Misha Mehta, MS Prital Patel, MPH Brian Wilkinson, MA Donna Beales, MLIS Jennifer De Lurio, MS Eloise DeHaan, BS Eileen Erinoff, MSLIS Cassia Hulshizer, AS Madison Kimball, MS Maria Middleton, MPH Diane Robertson, BA Melinda Rossi, BA Kelley Tipton, MPH Rosemary Walker, MLIS Andrew Furman, MD, MMM, FACEP Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the Horizon Scanning System has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions.
    [Show full text]
  • Expression of Rab Prenylation Pathway Genes and Relation to Disease Progression in Choroideremia
    Article Expression of Rab Prenylation Pathway Genes and Relation to Disease Progression in Choroideremia Lewis E. Fry1,2, Maria I. Patrício1,2, Jasleen K. Jolly1,2,KanminXue1,2,and Robert E. MacLaren1,2 1 Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford,UK 2 Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK Correspondence: Lewis E. Fry, Purpose: Choroideremia results from the deficiency of Rab Escort Protein 1 (REP1), Nuffield Department of Clinical encoded by CHM, involved in the prenylation of Rab GTPases. Here, we investigate Neuroscience, Level 6, West Wing, whether the transcription and expression of other genes involved in the prenylation John Radcliffe Hospital, Oxford, OX3 of Rab proteins correlates with disease progression in a cohort of patients with choroi- 9DU, UK. deremia. e-mail: [email protected]. Methods: Rates of retinal pigment epithelial area loss in 41 patients with choroideremia Received: February 9, 2021 were measured using fundus autofluorescence imaging for up to 4 years. From lysates of Accepted: May 9, 2021 cultured skin fibroblasts donated by patients (n = 15) and controls (n = 14), CHM, CHML, Published: July 13, 2021 RABGGTB and RAB27A mRNA expression, and REP1 and REP2 protein expression were Keywords: choroideremia; rab compared. escort protein 1 (REP1); inherited Results: The central autofluorescent island area loss in patients with choroideremia retinal degeneration; prenylation; occurred with a mean half-life of 5.89 years (95% confidence interval [CI] = 5.09–6.70), fundus autofluorescence with some patients demonstrating relatively fast or slow rates of progression (range = Citation: Fry LE, Patrício MI, Jolly JK, 3.3–14.1 years).
    [Show full text]
  • Public Summary of Opinion on Orphan Designation of Adeno-Associated
    1 June 2015 EMA/COMP/223562/2014 Rev.1 Committee for Orphan Medicinal Products Public summary of opinion on orphan designation Adeno-associated viral vector serotype 2 containing the human CHM gene encoding human Rab escort protein 1 for the treatment of choroideremia First publication 2 July 2014 Rev.1: administrative update 1 June 2015 Disclaimer Please note that revisions to the Public Summary of Opinion are purely administrative updates. Therefore, the scientific content of the document reflects the outcome of the Committee for Orphan Medicinal Products (COMP) at the time of designation and is not updated after first publication. On 4 June 2014, orphan designation (EU/03/14/1278) was granted by the European Commission to Alan Boyd Consultants Ltd, United Kingdom, for adeno-associated viral vector serotype 2 containing the human CHM gene encoding human Rab escort protein 1 for the treatment of choroideremia. What is choroideremia? Choroideremia is a hereditary disease of the eye that leads to progressive loss of sight. The disease mostly affects males. In patients with choroideremia, cells in the retina (the light-sensitive surface at the back of the eye), the retinal pigment epithelium (the cell layer just outside the retina that nourishes retinal cells) and the choroid (a network of blood vessels located between the retina and the sclera, the “white of the eye”) become damaged and eventually die. Chodoideraemia is a long-term debilitating disease because it causes the patient’s sight to worsen, eventually leading to blindness. What is the estimated number of patients affected by the condition? At the time of designation, choroideremia affected less than 0.2 people in 10,000 per year in the European Union (EU).
    [Show full text]
  • *TREATMENT of Lepro.SY with DIASONE-A PRELIMINARY REPORT
    SUNGEI BULOH LEPER HOSPITAL 17 lepers. They certainly threatened to do so with a regularity that never became monotonous. Indeed I canot recall a week during which they did not threaten to bomb-out or machine gun the whole settlement, The reason why the Japanese confined them­ selves to threats is simply told. The leper settlement contained patients from all over .the Federated Malay States. Under the British regime these various states paid so much per head per day for their lepers maintained at Sungei Buloh. This payment was continued under th.e occupation for the Japanese, terrified of infectious disease, would rather levy money than risk the return of lepers to their various districts. Except for a token payment for the maintenance ot Sungei Buloh this money was retained by the local Japanese Governor for his own use. It will be realised that if he retained one shilling per head per day (which is about correct) for a thousand patients, he was making' a profit of fifteen hundred pounds per month. And so the lepers were spared-they were profitable. When the end came the hospital wards were empty, for no-one was left able to care for the sick. Like wraiths over the untended paths, the patients came out of their houses with un­ certain eyes and waivering gait, to welcome their liberators. *TREATMENT OF LEPRo.SY WITH DIASONE-A PRELIMINARY REPORT By G. H. FAGET, M.D. and R. C. POGGE, M.D., Carville, La. Recently a number of new derivatives of diamino diphenyl sulfone have been tried in the chemotherapy.
    [Show full text]
  • International Standards for Tuberculosis Care (ISTC)
    INTERNATIONAL STANDARDS FOR Tuberculosis Care DIAGNOSIS TREATMENT PUBLIC HEALTH 3RD EDITION, 2014 Developed by TB CARE I with funding by the United States Agency for International Development (USAID) TB CARE I Organizations Disclaimer: The Global Health Bureau, Office of Health, Infectious Disease and Nutrition (HIDN), US Agency for International Development, financially supports this publication through TB CARE I under the terms of Agreement No. AID-OAA-A-10-00020. This publication is made possible by the generous support of the American people through the United States Agency for International Development (USAID). The contents are the responsibility of TB CARE I and do not necessarily reflect the views of USAID or the United States Government. Suggested citation: TB CARE I. International Standards for Tuberculosis Care, Edition 3. TB CARE I, The Hague, 2014. Contact information: Philip C. Hopewell, MD Curry International Tuberculosis Center University of California, San Francisco San Francisco General Hospital San Francisco, CA 94110, USA Email: [email protected] Available at the following web sites: http://www.tbcare1.org/publications http://www.istcweb.org http://www.currytbcenter.ucsf.edu/international http://www.who.int/tb/publications To access a mobile version of ISTC, go to www.walimu.org/istc INTERNATIONAL STANDARDS FOR Tuberculosis Care DIAGNOSIS TREATMENT PUBLIC HEALTH 3RD EDITION, 2014 Table of Contents Acknowledgments . 1 List of Abbreviations . 2 Preface . 4 Summary . 8 Introduction . 14 Standards for Diagnosis
    [Show full text]
  • The Antidepressant Sertraline Provides a Novel Host Directed Therapy Module For
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.26.115808; this version posted November 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The antidepressant sertraline provides a novel host directed therapy module for 2 augmenting TB therapy 3 Deepthi Shankaran1,2, Anjali Singh1,2, Stanzin Dawa1,2, Prabhakar A1,2, Sheetal Gandotra1,2, Vivek 4 Rao1,2* 5 1-CSIR- Institute of genomics and Integrative Biology, Mathura Road, New Delhi-110025 6 India. 7 2- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India 8 *Corresponding author: Tel: +91 11 29879229, E-mail: [email protected] 9 Key words: Mycobacterium tuberculosis/ host directed therapy/ antidepressant/ sertraline 10 Running Title: Sertraline augments antimycobacterial therapy 11 12 ABSTRACT: 13 A prolonged therapy, primarily responsible for development of drug resistance by Mycobacterium 14 tuberculosis (Mtb), obligates any new TB regimen to not only reduce treatment duration but also 15 escape pathogen resistance mechanisms. With the aim of harnessing the host response in 16 providing support to existing regimens, we used sertraline (SRT) to stunt the pro-pathogenic type 17 I IFN response of macrophages to infection. While SRT alone could only arrest bacterial growth, 18 it effectively escalated the bactericidal activities of Isoniazid (H) and Rifampicin (R) in 19 macrophages. This strengthening of antibiotic potencies by SRT was more evident in conditions 20 of ineffective control by these frontline TB drug, against tolerant strains or dormant Mtb. SRT, 21 could significantly combine with standard TB drugs to enhance early pathogen clearance from 22 tissues of mice infected with either drug sensitive/ tolerant strains of Mtb.
    [Show full text]